Pharma Accelerates AI Investment for Enterprise-Scale Deployment

Scaling GenAI in Pharma: From PoC to Enterprise Deployment

Scalability is a common issue facing pharma leaders who have deployed Generative AI (GenAI) applications as a proof of concept (PoC). Many are dazzled by their promise of streamlining staid work processes. Agentic AI and other new GenAI technologies can make PoCs faster and easier to launch, advancing scalability as well as security and development… The post Scaling pharma AI PoCs to enterprise deployments: Blending new tech with old-school rigo…

Big Pharma's AI Adoption Is Reaching a Tipping Point Amid Mounting Pressure and Strategic Opportunity, Finds New Report from Define Ventures

Define Ventures' new report reveals how C-suite pharma leaders are rapidly evolving their AI strategies — and what this acceleration means for Big Tech and health tech startups.

Pharma Accelerates AI Investment for Enterprise-Scale Deployment

What You Should Know:  – Define Ventures, one of the largest venture capital firms focused on early-stage health tech companies, today released a report revealing how Big Pharma is accelerating investment in AI to counter rising cost pressure, regulatory shifts, and growing competitive urgency.  – The report is based on in-depth surveys and interviews with over 40 executives, including leaders from 16 of the top 20 pharma companies and major pla…